Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3374890 | 0.89 | JAK2 (0.49) | JAK2JAK1 | |
| SCHEMBL3375100 | 0.89 | JAK2 (0.57) | JAK2JAK1 | |
| SCHEMBL3374832 | 0.86 | JAK2 (0.53) | JAK2JAK1 | |
| SCHEMBL3434304 | 0.84 | JAK2 (0.49) | JAK2JAK1 | |
| SCHEMBL3376933 | 0.83 | JAK2 (0.48) | JAK2JAK1 | |
| SCHEMBL14563896 | 0.80 | JAK2 (0.69) | JAK2JAK1 | |
| SCHEMBL3374032 | 0.80 | JAK2 (0.53) | JAK2JAK1 | |
| SCHEMBL3373671 | 0.80 | JAK2 (0.45) | JAK2JAK1 | |
| SCHEMBL14563475 | 0.80 | JAK2 (0.67) | JAK2JAK1 | |
| SCHEMBL3377511 | 0.80 | JAK1 (0.46) | JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013173506-A2 | METHOD OF TREATING MUSCULAR DEGRADATION | RIGEL PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | WO | disclosed |
| US-20130310340-A1 | METHOD OF TREATING MUSCULAR DEGRADATION | RIGEL PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| WO-2010039939-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | INCYTE CORPORATION (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310340-A1 | METHOD OF TREATING MUSCULAR DEGRADATION | PYGM, CKMT1A; CKMT1B, SMN1; SMN2 | JAK2 4729/4885JAK1 4796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.